Zymeworks Inc. (NASDAQ:ZYME) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Zymeworks Inc. (NASDAQ:ZYME) has been assigned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $38.2222.

A number of equities research analysts recently weighed in on ZYME shares. HC Wainwright lifted their price objective on shares of Zymeworks from $46.00 to $51.00 and gave the company a “buy” rating in a report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zymeworks in a research report on Friday, July 17th. Wells Fargo & Company lifted their price target on shares of Zymeworks from $37.00 to $40.00 and gave the company an “overweight” rating in a research note on Friday. Citigroup reiterated a “buy” rating on shares of Zymeworks in a report on Tuesday, June 30th. Finally, Truist Financial increased their price objective on Zymeworks from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday.

Zymeworks Stock Performance

Shares of NASDAQ:ZYME opened at $23.54 on Friday. The firm has a market cap of $1.72 billion, a price-to-earnings ratio of -11.65 and a beta of 1.15. The firm has a fifty day moving average price of $23.99 and a 200 day moving average price of $24.45. Zymeworks has a fifty-two week low of $11.51 and a fifty-two week high of $29.75.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). The business had revenue of $4.59 million during the quarter, compared to analysts’ expectations of $4.54 million. Zymeworks had a negative return on equity of 60.02% and a negative net margin of 405.31%.The business’s quarterly revenue was down 90.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.03 earnings per share. As a group, research analysts predict that Zymeworks will post 1.25 earnings per share for the current year.

Zymeworks announced that its board has authorized a share repurchase plan on Thursday, May 14th that permits the company to repurchase $125.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 7% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Institutional Investors Weigh In On Zymeworks

Institutional investors and hedge funds have recently made changes to their positions in the stock. AQR Capital Management LLC lifted its holdings in Zymeworks by 86.0% in the first quarter. AQR Capital Management LLC now owns 48,485 shares of the company’s stock valued at $577,000 after acquiring an additional 22,411 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Zymeworks by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 32,385 shares of the company’s stock valued at $386,000 after buying an additional 1,427 shares in the last quarter. Jane Street Group LLC increased its holdings in Zymeworks by 487.0% in the first quarter. Jane Street Group LLC now owns 135,763 shares of the company’s stock valued at $1,617,000 after buying an additional 112,636 shares in the last quarter. Creative Planning raised its position in shares of Zymeworks by 114.8% in the second quarter. Creative Planning now owns 25,389 shares of the company’s stock worth $319,000 after acquiring an additional 13,567 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of Zymeworks by 1,050.0% in the second quarter. JPMorgan Chase & Co. now owns 441,690 shares of the company’s stock worth $5,543,000 after acquiring an additional 403,281 shares during the period. 92.89% of the stock is currently owned by institutional investors and hedge funds.

More Zymeworks News

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Truist raises target and maintains a Buy rating: Truist Financial lifted its price target from $31 to $32, implying substantial upside from recent trading levels. The firm’s continued Buy recommendation may support investor confidence. Benzinga article
• Positive Sentiment: Analysts remain broadly bullish: HC Wainwright reiterated its Buy rating and $51 price target, while a separate brokerage report cited an average price target of $37.33. These targets suggest analysts see meaningful long-term value in Zymeworks despite near-term losses. Average price target article
• Neutral Sentiment: Revenue exceeded expectations: Zymeworks reported quarterly revenue of $4.59 million, ahead of the $3.81 million consensus estimate. However, the company remains unprofitable, limiting the positive impact of the revenue beat. Zacks earnings article
• Negative Sentiment: Quarterly loss was wider than expected: Zymeworks posted a loss of $0.62 per share, missing estimates for a $0.56–$0.57 loss and reversing year-earlier earnings of $0.03 per share. Revenue also declined 90.6% year over year, while the company reported a negative net margin and return on equity. Zymeworks earnings release
• Negative Sentiment: HC Wainwright cut earnings forecasts: The firm reduced its FY2026 EPS estimate from $1.00 to $0.36 and lowered its Q2 and Q4 forecasts to losses of $0.58 and $0.54 per share, respectively. It also trimmed its Q3 estimate to $2.09 from $2.17, signaling weaker near-term earnings expectations.

About Zymeworks

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.